Analysis of the average life expectancy of patients after using afatinib (Gitari)

Afatinib (Afatinib) is a second-generation irreversibleEGFR-TKI targeted drug, suitable for patients with EGFRAdvanced non-small cell lung cancer (NSCLC) patients with sensitive mutations (such asDel19 and L858R). Compared with the first generation EGFR-TKI (such as gefitinib and erlotinib), afatinib has a broader and more durable inhibitory effect on the EGFR family, and can irreversibly bind to the receptor, thereby more effectively inhibiting the growth and spread of tumor cells. This characteristic enables it to show better efficacy and survival benefit in first-line treatment.

Clinical trial data show that afatinib significantly prolonged the progression-free survival of EGFR mutation-positive NSCLC patients. In LUX-Lung 3 and LUX-Lung 6In the study, the median PFS of patients who received afatinib were 11.1 months and 11.0 span> months, while the PFS of chemotherapy in the control group were 6.9 months and 5.6 months respectively. This means that afatinib can delay disease progression by approximately 4~5 months, providing patients with more follow-up treatment time and quality of life.

In the long-term follow-up LUX-Lung trial, the overall survival (OS) of the afatinib treatment group was also significantly prolonged. Taking patients carrying EGFR Del19 mutations as an example, the median OS reached 31.7 months, while the median OS in the control group was 20.7 months, which was extended by nearly a year. For patients with L858R mutation, although OSThe lengthening was slightly smaller but still clinically significant. This shows that for patients with specific gene mutation types, afatinib can not only delay disease progression, but also actually extend overall survival time.

In addition to clinical trials, real-world studies also support the survival benefit of afatinib. In a number of retrospective studies of Asian populations, the overall survival time of NSCLC patients treated with afatinib as first-line treatment can generally reach more than 30 months, and some patients even exceed 3 years. Notably, the increased survival was related to the patient's mutation type, baseline health status, and subsequent treatment. Overall, afatinib provides a significant survival benefit for patients with EGFR mutation-positive lung cancer and is one of the important options for current standard first-line treatment.

Reference materials:https://www.drugs.com/